S&P 500   3,567.68 (+0.29%)
DOW   29,507.51 (+0.83%)
QQQ   290.11 (-0.09%)
AAPL   114.55 (-2.38%)
MSFT   209.59 (-0.38%)
FB   268.65 (-0.39%)
GOOGL   1,724.54 (-0.68%)
AMZN   3,098.78 (-0.02%)
TSLA   523.14 (+6.85%)
NVDA   524.42 (+0.17%)
BABA   270.63 (-0.04%)
CGC   25.03 (+5.52%)
GE   10.12 (+3.69%)
MU   63.87 (+4.02%)
AMD   84.89 (+0.30%)
T   28.59 (+0.95%)
NIO   54.10 (+9.85%)
F   8.87 (+1.49%)
ACB   7.42 (+4.07%)
GILD   59.57 (-0.90%)
NFLX   480.95 (-1.49%)
BA   210.94 (+5.67%)
DIS   146.10 (+3.57%)
S&P 500   3,567.68 (+0.29%)
DOW   29,507.51 (+0.83%)
QQQ   290.11 (-0.09%)
AAPL   114.55 (-2.38%)
MSFT   209.59 (-0.38%)
FB   268.65 (-0.39%)
GOOGL   1,724.54 (-0.68%)
AMZN   3,098.78 (-0.02%)
TSLA   523.14 (+6.85%)
NVDA   524.42 (+0.17%)
BABA   270.63 (-0.04%)
CGC   25.03 (+5.52%)
GE   10.12 (+3.69%)
MU   63.87 (+4.02%)
AMD   84.89 (+0.30%)
T   28.59 (+0.95%)
NIO   54.10 (+9.85%)
F   8.87 (+1.49%)
ACB   7.42 (+4.07%)
GILD   59.57 (-0.90%)
NFLX   480.95 (-1.49%)
BA   210.94 (+5.67%)
DIS   146.10 (+3.57%)
S&P 500   3,567.68 (+0.29%)
DOW   29,507.51 (+0.83%)
QQQ   290.11 (-0.09%)
AAPL   114.55 (-2.38%)
MSFT   209.59 (-0.38%)
FB   268.65 (-0.39%)
GOOGL   1,724.54 (-0.68%)
AMZN   3,098.78 (-0.02%)
TSLA   523.14 (+6.85%)
NVDA   524.42 (+0.17%)
BABA   270.63 (-0.04%)
CGC   25.03 (+5.52%)
GE   10.12 (+3.69%)
MU   63.87 (+4.02%)
AMD   84.89 (+0.30%)
T   28.59 (+0.95%)
NIO   54.10 (+9.85%)
F   8.87 (+1.49%)
ACB   7.42 (+4.07%)
GILD   59.57 (-0.90%)
NFLX   480.95 (-1.49%)
BA   210.94 (+5.67%)
DIS   146.10 (+3.57%)
S&P 500   3,567.68 (+0.29%)
DOW   29,507.51 (+0.83%)
QQQ   290.11 (-0.09%)
AAPL   114.55 (-2.38%)
MSFT   209.59 (-0.38%)
FB   268.65 (-0.39%)
GOOGL   1,724.54 (-0.68%)
AMZN   3,098.78 (-0.02%)
TSLA   523.14 (+6.85%)
NVDA   524.42 (+0.17%)
BABA   270.63 (-0.04%)
CGC   25.03 (+5.52%)
GE   10.12 (+3.69%)
MU   63.87 (+4.02%)
AMD   84.89 (+0.30%)
T   28.59 (+0.95%)
NIO   54.10 (+9.85%)
F   8.87 (+1.49%)
ACB   7.42 (+4.07%)
GILD   59.57 (-0.90%)
NFLX   480.95 (-1.49%)
BA   210.94 (+5.67%)
DIS   146.10 (+3.57%)
Log in
NYSE:AMRX

Amneal Pharmaceuticals Stock Forecast, Price & News

$4.07
-0.04 (-0.97 %)
(As of 11/23/2020 02:10 PM ET)
Add
Compare
Today's Range
$4.06
Now: $4.07
$4.16
50-Day Range
$4.01
MA: $4.54
$5.42
52-Week Range
$2.40
Now: $4.07
$5.79
Volume19,468 shs
Average Volume1.56 million shs
Market Capitalization$1.22 billion
P/E Ratio9.93
Dividend YieldN/A
Beta1.35
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120
Employees5,500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.12 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Market Cap$1.22 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$4.07
-0.04 (-0.97 %)
(As of 11/23/2020 02:10 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRX stock has increased by 25.5% and is now trading at $4.08.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Amneal Pharmaceuticals
.

What stocks does MarketBeat like better than Amneal Pharmaceuticals?

Wall Street analysts have given Amneal Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amneal Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) issued its quarterly earnings results on Friday, November, 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.04. The firm earned $519.30 million during the quarter, compared to the consensus estimate of $482.22 million. Amneal Pharmaceuticals had a net margin of 3.30% and a return on equity of 42.02%. The business's quarterly revenue was up 37.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.04 EPS.
View Amneal Pharmaceuticals' earnings history
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Friday, November, 6th. The company provided earnings per share (EPS) guidance of $0.45-0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.59. The company issued revenue guidance of $1.875-1.975 billion, compared to the consensus revenue estimate of $1.94 billion.

What price target have analysts set for AMRX?

10 brokerages have issued 1-year target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $3.00 to $7.00. On average, they expect Amneal Pharmaceuticals' share price to reach $5.19 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Chirag K. Patel, Co-Founder, Co-CEO, Pres & Director (Age 53, Pay $62.97k)
  • Mr. Chintu Patel R.Ph., R.Ph, Co-Founder, Co-CEO & Director (Age 48, Pay $64.6k)
  • Mr. Andrew S. Boyer, Exec. VP & Chief Commercial Officer of Generics (Age 54, Pay $675.09k)
  • Mr. Anastasios G. Konidaris, Exec. VP & CFO (Age 53)
  • Mr. Stephen J. Manzano, Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.78%), Neuberger Berman Group LLC (1.23%), State Street Corp (0.83%), LSV Asset Management (0.37%), Charles Schwab Investment Management Inc. (0.24%) and Wells Fargo & Company MN (0.12%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which major investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Assenagon Asset Management S.A., BlackRock Inc., State Street Corp, Connor Clark & Lunn Investment Management Ltd., BNP Paribas Arbitrage SA, Neuberger Berman Group LLC, and Paloma Partners Management Co.
View insider buying and selling activity for Amneal Pharmaceuticals
.

Which major investors are buying Amneal Pharmaceuticals stock?

AMRX stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, LSV Asset Management, Morgan Stanley, Squarepoint Ops LLC, Hussman Strategic Advisors Inc., Wells Fargo & Company MN, Victory Capital Management Inc., and WINTON GROUP Ltd. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.08.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.22 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.